Skip to main content

Table 3 Antimicrobial susceptibility of the 83 S. pneumoniae isolates to 17 antimicrobial agents

From: Genotypic and phenotypic characteristics of Streptococcus pneumoniae from community-acquired pneumonia patients and healthy asymptomatic participants in Sichuan province, China

Antimicrobial agentsa Total (n = 83) Asymptomatic carriers (n = 52) CAP carriers (n = 31) P value
Sb I R S I R S I R
ERY 0 (0.0) 0 (0.0) 83 (100.0) 0 (0.0) 0 (0.0) 52 (100.0) 0 (0.0) 0 (0.0) 31 (100.0) –
CLI 0 (0.0) 0 (0.0) 83 (100.0) 0 (0.0) 0 (0.0) 52 (100.0) 0 (0.0) 0 (0.0) 31 (100.0) –
SXT 13 (15.7) 12 (14.5) 58 (69.9) 8 (15.4) 7 (13.5) 37 (71.2) 5 (16.1) 5 (16.1) 21 (67.7) 0.935
TET 13 (15.7) 6 (7.2) 64 (77.1) 12 (23.1) 2 (3.8) 38 (73.1) 1 (3.2) 4 (12.9) 26 (83.9) 0.014
CXM 38 (45.8) 10 (12.0) 35 (42.2) 27 (51.9) 8 (15.4) 17 (32.7) 11 (35.5) 2 (6.5) 18 (58.1) 0.065
CHL 75 (90.4) 0 ( (0.0) 8 (9.6) 47 (90.4) 0 (0.0) 5 (9.6) 28 (90.3) 0 (0.0) 3 (9.7) 0.993
CEF 68 (81.9) 5 (6.0) 10 (12.0) 47 (90.4) 1 (1.9) 4 (7.7) 21 (67.7) 4 (12.9) 6 (19.4) 0.028
PEN 24 (28.9) 38 (45.8) 21 (25.3) 15 (28.8) 29 (55.8) 8 (15.4) 9 (29.0) 9 (29.0) 13 (41.9) 0.015
CRO (Non-meningitis) 81 (97.6) 1 (1.2) 1 (1.2) 52 (100.0) 0 (0.0) 0 (0.0) 29 (93.5) 1 (3.2) 1 (3.2) 0.134
MER 74 (89.2) 8 (9.6) 1 (1.2) 47 (90.4) 4 (7.7) 1 (1.9) 27 (87.1) 4 (12.9) 0 (0.0) 0.475
CFP (Non-meningitis) 72 (86.7) 10 (12.0) 1 (1.2) 48 (92.3) 4 (7.7) 0 (0.0) 24 (77.4) 6 (19.4) 1 (3.2) 0.102
MOX 83 (100.0) 0 (0.0) 0 (0.0) 52 (100.0) 0 (0.0) 0 (0.0) 31 (100.0) 0 (0.0) 0 (0.0) –
LEV 82 (98.8) 1 (1.2) 0 (0.0) 51 (98.1) 1 (1.9) 0 (0.0) 31 (100.0) 0 (0.0) 0 (0.0) 1.000
VAN 81 (97.6) 0 (0.0) 2 (2.4) 52 (100.0) 0 (0.0) 0 (0.0) 29 (93.5) 0 (0.0) 2 (6.5) 0.137
RIF 79 (95.2) 2 (2.4) 2 (2.4) 51 (98.1) 1 (1.9) 0 (0.0) 28 (90.3) 1 (3.2) 2 (6.5) 0.123
AMPC/CVA (Non-meningitis) 80 (96.4) 3 (3.6) 0 (0.0) 51 (98.1) 1 (1.9) 0 (0.0) 29 (93.5) 2 (6.5) 0 (0.0) 0.553
LIN 79 (95.2) 0 (0.0) 4 (4.8) 50 (96.2) 0 (0.0) 2 (3.8) 29 (93.5) 0 (0.0) 2 (6.5) 0.995
  1. aERY erythromycin, CLI clindamycin, SXT trimethoprim-sulfamethoxazole, TET tetracycline, CXM cefuroxime, CHL chloramphenicol, CEF cefotaxime, PEN penicillin, CRO ceftriaxone, MER meropenem, CFP cefepime, MOX moxifloxacin, LEV levofloxacin, VAN vancomycin, RIF rifampicin, AMPC/CVA amoxicillin/clavulanic acid, LIN linezolid
  2. bI intermediate, R resistant, S susceptible
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us